This is a preclinical announcement with no near-term revenue or partnership catalyst. Monitor the November 2026 PEGS Europe data presentation for potential proof-of-concept validation. The company remains a clinical-stage entity with no approved products or disclosed revenue, so the stock will likely trade on pipeline milestones and financing needs.
Price Chart
Executive Summary
Evaxion announced it is applying its AI-Immunology platform to autoimmune diseases, testing two novel treatment concepts (tolerogenic vaccine and autoantibody binder). Initial experimental data is expected at PEGS Europe in November 2026. This is a preclinical pipeline expansion with no financial data or near-term catalyst, representing a modest strategic update for a clinical-stage company.
Key Facts
- Evaxion is applying its AI-Immunology platform to autoimmune diseases, expanding beyond cancer and infectious diseases.
- Two novel concepts are being tested: a tolerogenic vaccine and an autoantibody binder.
- Initial experimental data will be presented at PEGS Europe in Lisbon on November 18, 2026.
- No financial terms, partnership agreements, or clinical trial data were disclosed in the filing.
Financial Impact
No financial impact disclosed; preclinical platform expansion with no revenue or cost figures provided.
Risk Factors
- Preclinical platform expansion carries high technical risk; no guarantee of successful development or partnership.
- Evaxion's need for additional capital is explicitly noted in forward-looking statements, posing dilution risk.
- No financial data or guidance was provided, limiting the ability to assess fundamental value.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006028 |
| Document: f6k_091426.htm | 0001171843-26-006028 |
| Document: 0001171843-26-006028-index-headers.html | 0001171843-26-006028 |
| Document: 0001171843-26-006028-index.html | 0001171843-26-006028 |
| Document: 0001171843-26-006028.txt | 0001171843-26-006028 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $3.07 $3.21 | ▲ +4.56% | ▲ +4.45% | $3.21 (+4.63%) |
Sep 4, 2026 28d ago | 6-K | $3.12 $3.07 | ▲ +1.60% | ▲ +0.39% | $3.21 (−2.96%) |
Aug 20, 2026 6w ago | 6-K | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 20, 2026 6w ago | Press Release | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.21 (−2.07%) |
Aug 17, 2026 6w ago | 6-K | $3.13 $3.40 | ▲ +8.63% | ▲ +9.82% | $3.21 (+2.63%) |
Aug 14, 2026 7w ago | 6-K | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Aug 14, 2026 7w ago | Press Release | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.21 (−3.83%) |
Jul 17, 2026 11w ago | 6-K | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 17, 2026 11w ago | Press Release | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.21 (+4.46%) |
Jul 13, 2026 11w ago | 6-K | $3.02 $3.08 | ▲ +1.82% | ▲ +2.61% | $3.21 (+6.36%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access